RECRUITING STUDIES

Clinical trials at The Polyclinic are open to both Polyclinic patients and the public. Trials are conducted by a Polyclinic physician and supported by a study coordinator employed by The Polyclinic.  Currently enrolling trials are listed below.

If you are interested in participating in an enrolling trial, please contact the designated study coordinator or The Polyclinic Clinical Research Department at research@polyclinic.com or (206) 320-6692.

If you qualify for a trial and are enrolled, you will receive confidential study-related medical care (and study treatment if applicable) at no cost. Financial compensation may also be provided. 

 

Asthma

Dr. Curtis Veal is conducting a study for patients with asthma. The study evaluates the risk of serious asthma-related events during treatment with the study drug (a combination of two drugs, inhaled corticosteroid and a type of bronchodilator called a long-acting beta agonist) as compared to treatment with inhaled corticosteroid alone in the treatment of asthma.

For additional information, please go to: http://www.clinicaltrials.gov/ct2/show/NCT01444430?term=D5896C00027&rank=1.

Principal Investigator: Curtis Veal, MD
Sub-Investigators: Linda Anderson, MD; Charles Lee, MD; Samuel Nadler, MD; Embra Roper, MD
Study Coordinator: Gary Brown, CMA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Celiac Disease

Dr. Craig Pepin is conducting a study for patients with celiac disease maintained on a gluten-free diet who have experienced at least one moderate or severe symptom in the past month. The study evaluates the effectiveness and safety of an investigational agent (administered orally) in the management of celiac disease.

For additional information, please go to: http://www.clinicaltrials.gov/ct2/show/NCT01917630?term=ALV003-1221&rank=1

Principal Investigator: Craig Pepin, MD
Study Coordinator: Gary Brown, CMA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Diabetes (Type 2)

Dr. Ken Gross is conducting a study for type 2 diabetes patients. The study evaluates the effectiveness of an investigational agent (self-administered subcutaneously) on glycemic control in patients with type 2 diabetes.

For additional information, please go to: http://www.clinicaltrials.gov/ct2/show/NCT02152371?term=H9X-MC-GBDI&rank=1.

Principle Investigator: Ken Gross, MD
Sub-Investigator: Michael Williams, MD
Study Coordinator: Gary Brown, CMA
Phone: (206) 860-4761
E-mail: research@polyclinic.com

 

Multiple Sclerosis (Relapsing)

Dr. Braden Nago is conducting a study for patients with relapsing MS. The study evaluates the effectiveness and safety of an investigational agent (administered orally) in the treatment of relapsing MS.

For additional information, please go to: http://www.clinicaltrials.gov/ct2/show/NCT02047734?term=RPC01-201&rank=1

Principle Investigator: Braden Nago, MD
Sub-Investigators: Alex Cooper, MD; Sameer Khan, MD; Anthony Krajcer, MD; Benduan Yang, MD
Study Coordinator: Michelle Harder, CMA
Phone: (206)860-5432
E-mail: research@polyclinic.com

 

Overactive Bladder 

Dr. Emily Bradley is conducting a study for patients with overactive bladder and urinary incontinence. The study evaluates the relative safety and effectiveness of Botox in achieving 100% reduction in urinary incontinence.

For additional information, please go to: http://www.clinicaltrials.gov/ct2/show/NCT01945489?term=GMA-OAB-113&rank=1.

Principal Investigator: Emily Bradley, MD
Sub-Investigator: Van Ginger, MD, PhD
Study Coordinator: Victoria Saetern, CMA 
Phone: (206) 320-6752
E-mail: research@polyclinic.com

 

Psoriatic Arthritis

Dr. Anthony Krajcer is conducting a study for patients with psoriatic arthritis. The study evaluates the effectiveness and safety of an investigational agent (administered subcutaneously) in treating psoriatic arthritis.

For additional information, please go to: http://www.clinicaltrials.gov/ct2/show/NCT02024646?term=20110144&rank=1

Principal Investigator: Anthony Krajcer, MD
Study Coordinator: Michelle Harder, CMA
Phone: (206) 860-5432
E-mail: research@polyclinic.com

 

Calculation of Warfarin Dose Using Genetic Information

Dr. Christopher Cannon is conducting a study to determine if the use of genetic information related to warfarin sensitivity can help create a dose of warfarin that will result in less hospitalizations and deaths related to warfarin.

For additional information, please go to: http://www.clinicaltrials.gov/ct2/show/NCT01305148?term=IG-0109&rank=1

Principal Investigator: Christopher Cannon, MD
Sub-Investigator: Melissa Hull, PharmD
Study Coordinator: Victoria Saetern, CMA 
Phone: (206) 320-6752 
E-mail: research@polyclinic.com